

**Request for Prior Authorization
IL-5 ANTAGONISTS**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax	NDC

Prior authorization is required for IL-5 antagonists. Requests will not be considered with concurrent use with another monoclonal antibody. Payment will be considered under the following conditions:

- 1) Patient meets the FDA approved age for submitted diagnosis; and
- 2) Is dosed within FDA approved dosing for submitted diagnosis and age; and
- 3) Patient has a diagnosis of severe asthma with an eosinophilic phenotype; and
 - a) Patient has a pretreatment blood eosinophil count of ≥ 150 cells per mL within the previous 6 weeks or blood eosinophils of ≥ 300 cells per mL within 12 months prior to initiation of therapy; and
 - b) Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (long-acting beta2-agonist [LABA] and leukotriene receptor antagonist [LTRA]) for a minimum of 3 consecutive months, with or without oral corticosteroids. Patient must be compliant with therapy, based on pharmacy claims; and
 - c) Patient has a history of two (2) or more exacerbations in the previous year despite regular use of high-dose ICS plus a LABA and LTRA; and
 - d) A pretreatment forced expiratory volume in 1 second (FEV₁) $< 80\%$ predicted in adults and $< 90\%$ in adolescents; or
- 4) Patient has a diagnosis of eosinophilic granulomatosis with polyangiitis; and
 - a) Patient has documentation of an adequate trial and therapy failure with systemic glucocorticoids; and
 - b) One of the following:
 - i. Eosinophil count greater than 1000 cells/mL; or
 - ii. Eosinophil count greater than 10% of the total leukocyte count; and
- 5) Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist.

If the criteria for coverage are met, an initial authorization will be given for 3 months to assess the need for continued therapy. Requests for continuation of therapy will be based on continued medical necessity and will be considered when the following criteria are met:

Severe Asthma with an Eosinophilic Phenotype:

- 1) Patient continues to receive therapy with an ICS, LABA and LTRA; and
- 2) Patient has experienced a reduction in asthma signs and symptoms including wheezing, chest tightness, coughing, shortness of breath; or
- 3) Patient has experienced a decrease in administration of rescue medication (albuterol); or
- 4) Patient has experienced a decrease in exacerbation frequency; or
- 5) Patient has experienced an increase in predicted FEV₁ from the pretreatment baseline.

Eosinophilic Granulomatosis with Polyangiitis:

- 1) Patient has demonstrated a positive clinical response to therapy (increase in remission time).

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Request for Prior Authorization IL-5 ANTAGONISTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Preferred

Non-Preferred

Fasenra Auto-Injector

Nucala Auto-Injector

Nucala Prefilled Syringe

Strength

Dosage Instructions

Quantity

Days Supply

Diagnosis:

Is prescriber and allergist, immunologist, pulmonologist, or rheumatologist?

Yes, document specialty:

No If no, note consultation with specialist:

Consultation Date: Physician Name, Specialty & Phone:

Will the patient be taking requested medication in combination with another monoclonal antibody? No Yes

Severe Asthma with an Eosinophilic Phenotype:

Pretreatment blood eosinophil count (attach lab): Date Obtained:

OR

Blood eosinophil count obtained within 12 months prior to initiation of treatment (attach lab):

Date Obtained:

Pretreatment Baseline ppFEV1: Date Obtained:

Document current use of:

High-dose inhaled corticosteroid: Drug Name: Strength:

Dosing Instructions: Trial start date:

Long-Acting Beta2-Agonist: Drug Name: Strength:

Dosing Instructions: Trial start date:

Leukotriene Receptor Antagonist: Drug Name: Strength:

Dosing Instructions: Trial start date:

Does patient have a history of two (2) or more exacerbations in the previous year despite regular use of high-dose ICS plus a LABA and LTRA? No Yes (provide dates):

Eosinophilic Granulomatosis with Polyangiitis:

Document trial of systemic glucocorticoid: Drug Name: Strength:

Dosing Instructions: Trial start & end date:

Pretreatment blood eosinophil count (attach lab): Date Obtained:

OR

Eosinophil count greater than 10% of the total leukocyte count (attach lab): Date Obtained:

**Request for Prior Authorization
IL-5 ANTAGONISTS**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

For Renewals Only:

Severe Asthma with an Eosinophilic Phenotype:

Does patient continue to receive therapy with an ICS, LABA and LTRA? No Yes

Please indicate if the patient has experienced any of the following (check all that apply):

- Reduction in asthma signs and symptoms including:
 - wheezing
 - chest tightness
 - coughing
 - shortness of breath
- Decrease in administration of rescue medications (albuterol)
- Decrease in exacerbation frequency
- Increase in ppFEV₁ from the pretreatment baseline Current ppFEV₁: _____ Date Obtained: _____

Please describe: _____

Eosinophilic Granulomatosis with Polyangiitis:

Has patient demonstrated a positive clinical response to therapy (increase in remission time)?

- No
- Yes, please describe: _____

Medical or contraindication reason to override trial requirements: _____

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.